Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib

The Bruton tyrosine kinase (BTK) inhibitor ibrutinib improves patient outcomes in chronic lymphocytic leukemia (CLL); however, some patients experience adverse events (AEs) leading to discontinuation. Acalabrutinib is a potent, covalent BTK inhibitor with greater selectivity than ibrutinib. We evalu...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood Adv
Main Authors: Awan, Farrukh T., Schuh, Anna, Brown, Jennifer R., Furman, Richard R., Pagel, John M., Hillmen, Peter, Stephens, Deborah M., Woyach, Jennifer, Bibikova, Elena, Charuworn, Prista, Frigault, Melanie M., Hamdy, Ahmed, Izumi, Raquel, Linghu, Bolan, Patel, Priti, Wang, Min Hui, Byrd, John C.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2019
Fag:
Clinical Trials and Observations
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6517672/
https://ncbi.nlm.nih.gov/pubmed/31088809
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018030007
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker